| Date | Title | Description | |
|---|---|---|---|
| 10 May 2023 | Announcement of General Shareholders’ Meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
| 21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
| 21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Nov 2016 | Información sobre resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2016 results | Download |
| 08 Nov 2016 | Información sobre resultados (2) | ROVI releases the press release related to the nine-month period ended 30 September 2016 results | Download |
| 08 Nov 2016 | Otros sobre Gobierno Corporativo | The Company informs about the agreement of the Board of Directors with regards to the appointment of the Accounts Auditor | Download |
| 04 Oct 2016 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2016 | Download |
| 01 Aug 2016 | Acuerdos estratégicos con terceros | ROVI announces the marketing agreement of Mysimba in Spain | Download |